NIOX Group (LSE:NIOX) EBIT per Share : £0.01 (TTM As of Dec. 2023)

View and export this data going back to 2014. Start your Free Trial

What is NIOX Group EBIT per Share?

NIOX Group's EBIT per Share for the six months ended in Dec. 2023 was £0.00. Its EBIT per Share for the trailing twelve months (TTM) ended in Dec. 2023 was £0.01.

During the past 12 months, the average EBIT per Share Growth Rate of NIOX Group was 150.00% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.

The historical rank and industry rank for NIOX Group's EBIT per Share or its related term are showing as below:

During the past 13 years, the highest 3-Year average EBIT per Share Growth Rate of NIOX Group was 58.00% per year. The lowest was -49.00% per year. And the median was -1.00% per year.

LSE:NIOX's 3-Year EBIT Growth Rate is not ranked ^*
in the Medical Devices & Instruments industry.
Industry Median: 5.6
* Ranked among companies with meaningful 3-Year EBIT Growth Rate only.

NIOX Group's EBIT for the six months ended in Dec. 2023 was £1.20 Mil.

NIOX Group EBIT per Share Historical Data

The historical data trend for NIOX Group's EBIT per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

NIOX Group EBIT per Share Chart

NIOX Group Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

EBIT per Share

Get a 7-Day Free Trial

-0.07

-0.05

-0.01

0.02

0.01

NIOX Group Semi-Annual Data
	Jun14	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
EBIT per Share	Get a 7-Day Free Trial															-	0.02	-	0.01	-

NIOX Group EBIT per Share Calculation

EBIT per Share is the amount of Earnings Before Interest and Taxes (EBIT) per outstanding share of the company's stock.

Earnings Before Interest and Taxes (EBIT) is what the company earns before it expenses interest and taxes.

NIOX Group's EBIT per Share for the fiscal year that ended in Dec. 2023 is calculated as

	EBIT per Share		(A: Dec. 2023 )
=	EBIT	/	Shares Outstanding (Diluted Average)
=	4.2	/	449.278
=	0.01

NIOX Group's EBIT per Share for the quarter that ended in Dec. 2023 is calculated as

	EBIT per Share		(Q: Dec. 2023 )
=	EBIT	/	Shares Outstanding (Diluted Average)
=	1.2	/	449.193
=	0.00

EBIT per Share for the trailing twelve months (TTM) ended in Dec. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was £0.01

NIOX Group (LSE:NIOX) EBIT per Share Explanation

EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.

NIOX Group EBIT per Share Related Terms

Thank you for viewing the detailed overview of NIOX Group's EBIT per Share provided by GuruFocus.com. Please click on the following links to see related term pages.

NIOX Group (LSE:NIOX) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » NIOX Group PLC (LSE:NIOX) » Definitions » EBIT per Share

Comparable Companies

Traded in Other Exchanges

82C:Germany

Address

Edmund Halley Road, Hayakawa Building, The Oxford Science Park, Oxford, GBR, OX4 4GB

Website

https://investors.niox.com

NIOX Group PLC is a medical device company that develops a range of therapies for asthma, chronic obstructive pulmonary disease, and allergy. The company has a single operating segment: NIOX. The NIOX segment relates to the portfolio of products used to improve asthma diagnosis and management by measuring fractional exhaled nitric oxide (FeNO). Geographically, it derives a majority of its revenue from the Asia Pacific and also has a presence in the European Union, the United States, the United Kingdom, and the Rest of the world.

NIOX Group (LSE:NIOX) Headlines

No Headlines